We will exhibit at the 3rd Annual mRNA-Based Therapeutics Summit.
Please visit our poster booth when you attend the summit.

[Overview of the Summit] https://mrnabased-therapeutics.com/

---

[Date] July 26-28, 2023

[Title] mRNA medicine development strategy as Japan’s first CRDMO Strategy for optimization of mRNA design

Akiko Yanagiya, Rena Akahori, Naoki Matsumoto, Daichi Matsuura, Tetsuo Yoshida, Jun Nihira, Kazuyuki Nakashima

[Abstract] 

ARCALIS is the first GMP compliant CRDMO for mRNA-based therapeutics in Japan, which was established in April 2021 in Kashiwanoha, Chiba, Japan. ARCALIS is a joint-venture of Axcelead (an integrated drug discovery platformer curved-out from Takeda pharmaceutical research division) and Arcturus (a unique manufacturing and process technology company for mRNA drug substance and LNP formulation. ARCALIS can provide mRNA-based therapeutics from CMC development to GMP-manufacturing seamlessly. Here, we present our capabilities for developing mRNA medicines in terms of mRNA design, quality controls such as capping efficiency, the length of poly(A) tail and a potency assay for protein production.